Calpain inhibitor 2 prevents axonal degeneration of opossum optic nerve fibers.
The ultrastructural change that characterizes the onset of Wallerian degeneration is the disintegration of axoplasmic microtubules and neurofilaments, which are converted into an amorphous and granular material, followed by myelin breakdown. The mechanism underlying such processes is an increase in the amount of intracellular calcium, leading to activation of proteases called calpains. The aim of this study was to evaluate by quantitative ultrastructural analysis whether nerve fibers can be preserved by the use of an exogenous inhibitor of these proteases (calpain inhibitor-2, Mu-F-hF-FMK), after optic nerve crush. For that, the left optic nerves of opossums, Didelphis aurita, were crushed with the aid of a fine forceps, and half of them received a calpain inhibitor mixed with Elvax resin. Ninety-six hours after the lesion, the animals were reanesthetized and transcardially perfused, and the optic nerves were removed, the right ones being used as normal nerves. Afterward, the optic nerves were dissected and processed for routine transmission electron microscopy and quantitative and statistical analysis. The results of this analysis showed that the group that received the calpain inhibitor presented a reduction of astrogliosis, maintaining the optic nerve structure in an organized state; a significant decrease in the number of degenerating fibers; and a significant increase in the number of fibers with preserved cytoskeleton and preservation of axonal and myelin area and integrity, reducing the enlargement and edema of the axon. In conclusion, our findings suggest that calpain inhibitor is able to provide neuroprotection of the central nervous system fibers after a crush lesion.
Araújo Couto
Luciana
L
Departamento de Histologia e Embriologia, Instituto de Ciências Biomédicas, Centro de Ciências da Saúde, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brasil.
Sampaio Narciso
Marcelo
M
Hokoç
Jan Nora
JN
Blanco Martinez
Ana Maria
AM
D000818:Animals; D001369:Axons / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure; D002154:Calpain / Q000037:antagonists & inhibitors*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D009409:Nerve Crush / Q000379:methods; D009410:Nerve Degeneration / Q000201:enzymology / Q000473:pathology / Q000517:prevention & control*; D009413:Nerve Fibers, Myelinated / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure; D009842:Oligopeptides / Q000494:pharmacology* / Q000627:therapeutic use; D009893:Opossums; D009900:Optic Nerve / Q000187:drug effects* / Q000201:enzymology / Q000648:ultrastructure
D015853:Cysteine Proteinase Inhibitors; D009842:Oligopeptides; C069861:calpain inhibitor 2; D002154:Calpain